ZELTIQ™(NASDAQ: ZLTQ) is medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat. The device is cleared by the FDA in the United States for various applications related to skin cooling during dermatologic treatments, with a pending application for non-invasive body fat reduction. Based on a method to kill…

Selecta Biosciences, Inc.is developing first-in-class integrated synthetic nanoparticle vaccines using its proprietary targeted Synthetic Vaccine Particle (tSVP™) technology. Selecta’s synthetic nanoparticle vaccines enable expanded opportunities for both the treatment and prevention of a wide range of human diseases including infectious, CNS, metabolic and inflammatory diseases.

Symbiotix Biotherapies, Inc. is developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. The company’s lead program represents the first molecule to emerge from the human microbiome, and is a first-in-class oral agent for the treatment of serious immune-mediated diseases.

T2 Biosystems T2 Biosystems (NASDAQ: TTOO) is a biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MR) technology to provide rapid, accurate and portable diagnostics.

Verinata Health, Inc. (acquired by Illumina, Inc.) developed non-invasive tests for the early identification of fetal chromosomal abnormalities.

Fate Therapeutics (NASDAq: FATE) is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop stem cell modulators, small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative…

GeneInsight is an IT platform developed to streamlines interpretation and management of vast amounts of data clinical genomic data, offering a key step towards the promise of personalized medicine and better patient care.

MoMelan Technologies (acquired by Kinetic Concepts, Inc.) has developed a novel skin grafting technology to treat skin disorders through the expansion of the surface area of skin grafts.

NinePoint Medical, Inc. is a medical device company integrating multiple technologies to streamline patient care. NinePoint is initially developing novel products for use during minimally invasive procedures such as endoscopy and laparoscopy to provide enhanced diagnostic capabilities and improve outcomes.

NKT Therapeutics is a biotechnology company focused on developing therapeutics based on a unique subset of immune cells called natural killer T (”NKT”) cells.

OvaScience (NASDAQ: OVAS) is a global life sciences company dedicated to improving fertility for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments.

Seven Oaks Biosystems is an early stage venture developing a minimally invasive device for autologous full-thickness skin transplant for wound healing and reconstructive surgery.